Pharmaceutical - Markets & Marketing, North America

Filter

Popular Filters

1 to 25 of 220 results

Astellas settles with US DoJ over Mycamine marketing

Astellas settles with US DoJ over Mycamine marketing

17-04-2014

The US subsidiary of Japanese drug major Astellas Pharma will pay $7.3 million to resolve allegations…

Antibiotics and Infectious diseasesAstellas PharmaLegalMarkets & MarketingMycamineNorth AmericaPharmaceuticalUSA

Total spending growth returns for US medicines, reports IMS Health

Total spending growth returns for US medicines, reports IMS Health

15-04-2014

Total spending on US medicines increased 1.0% on a real per capita basis in 2013, while the use of health…

FinancialHealthcareMarkets & MarketingNorth AmericaPharmaceuticalUSA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

Generic drugs slow pharma spending growth in Canada

Generic drugs slow pharma spending growth in Canada

13-03-2014

Last year, C$29.3 billion ($26.47 billion) was spent on prescription drugs in Canada, but the annual…

CanadaFinancialGenericsMarkets & MarketingNorth AmericaPharmaceutical

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

04-03-2014

US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

US orphan drug market outlook 2018: Report

25-02-2014

In the largest market for orphan drugs, the USA, there was a shortage of adequate therapies for treating…

Markets & MarketingNorth AmericaPharmaceuticalRare diseasesRegulationUSA

Taking a cue from Apple and Coca-Cola, Big Pharma are humanizing brands

05-02-2014

By 2018, it is estimated that the global pharmaceutical market will be worth more than $1.3 trillion.…

Markets & MarketingNorth AmericaPharmaceuticalUSA

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Eisai’s epilepsy drug Fycompa to launch in USA

Eisai’s epilepsy drug Fycompa to launch in USA

02-01-2014

The US subsidiary of Japanese pharma major Eisai’s that its epilepsy drug Fycompa (perampanel) will…

EisaiFycompaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalUSA

Abbott Labs pays $5.5 million to settle claims it paid kickbacks to US physicians

Abbott Labs pays $5.5 million to settle claims it paid kickbacks to US physicians

29-12-2013

US drugmaker Abbott Laboratories has agreed to pay $5.475 million to resolve allegations that it violated…

LegalMarkets & MarketingNorth AmericaPharmaceuticalUSA

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth

20-12-2013

The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

Forest debuts MMD drug Fetzima in US pharmacies

19-12-2013

US drugmaker Forest Laboratories says that Fetzima (levomilnacipran ER capsules) is now available in…

FetzimaForest LaboratoriesMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPierre FabreUSA

United Therapeutics subpoenaed over drug marketing practices

09-12-2013

US drugmaker United Therapeutics says it has received a subpoena from the Office of the Inspector General…

AdcircaLegalMarkets & MarketingNorth AmericaPharmaceuticalRemodulinTyvasoUnited Therapeutics

Review of key drivers of migraine market growth through 2022

06-12-2013

Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

US patient share leaders in first-line BRAF-mutation positive malignant melanoma

27-11-2013

According to US oncologists surveyed in the third quarter of 2013 by BioTrends Research, a unit of Decision…

Bristol-Myers SquibbGlaxoSmithKlineMarkets & MarketingMekinistNorth AmericaOncologyPharmaceuticalRocheTafinlarYervoyZelboraf

Drug Quality and Security Act passes in US Senate

20-11-2013

After months of discussion in the US Congress, finally HR 3204, the Drug Quality and Security Act, which…

LegalMarkets & MarketingNorth AmericaPharmaceuticalProduction

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019

13-11-2013

The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Incidence of post-herpetic neuralgia set for steady increase by 2022

11-11-2013

Due to the growth of the elderly population worldwide, the number of post-herpetic neuralgia (PHN) incident…

Asia-PacificEuropeMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Through 2022, growth in the neuropathic pain drug market will be constrained by generics

05-11-2013

The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

Johnson & Johnson to pay over $2.2 billion to settle DoJ probe

05-11-2013

Global health care giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion to resolve…

FinancialInvegaJanssenJohnson & JohnsonLegalMarkets & MarketingNatrecorNorth AmericaPharmaceuticalRisperdalScios

Actelion says PAH drug Opsumit now available in USA

Actelion says PAH drug Opsumit now available in USA

05-11-2013

Actelion has confirmed that Opsumit 10mg, an oral, dual endothelin receptor antagonist for pulmonary…

ActelionMarkets & MarketingNorth AmericaOpsumitPharmaceuticalRespiratory and Pulmonary

Sagent Pharma debuts Carboplatin Injection

Sagent Pharma debuts Carboplatin Injection

04-11-2013

US specialty drugmaker Sagent Pharmaceuticals has announced the launch of Carboplatin Injection, an antineoplastic…

Asia-PacificCarboplatinMarkets & MarketingNorth AmericaOncologyPharmaceuticalProductionSagent Pharmaceuticals

Ariad Pharma “temporarily” suspends only marketed drug Iclusig in USA

Ariad Pharma “temporarily” suspends only marketed drug Iclusig in USA

01-11-2013

US drugmaker Ariad Pharmaceutical says it temporarily suspending the marketing and commercial distribution…

Ariad PharmaceuticalsIclusigMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulation

1 to 25 of 220 results

Parexel

Parexel

Back to top